L. Michael Glodé, MD, FACP

L. Michael Glodé, MD, FACP

University of Colorado Cancer Center

Aurora, Colorado

Dr. Glodé is Professor Emeritus of Medical Oncology and the former Robert Rifkin Chair for Prostate Cancer Research at the University of Colorado Cancer Center in Aurora, Colorado. He was the first board-certified medical oncologist at the University of Colorado, joining the faculty after training at the Dana-Farber Cancer Institute in Boston. Dr. Glodé’s research has been clinically focused on prostate cancer for many years. He headed the initial research on leuprolide, leading to its approval. He has also led efforts to evaluate a natural product, silibinin, as a preventive or therapeutic agent. He has been an investigator on more than 30 clinical trials, including the PI position for one of the largest adjuvant trials in prostate cancer, SWOG 9921. Dr. Glodé has received numerous teaching awards and founded the AACR course “Molecular Biology for Clinical Oncologists.” He has also served as Founding Editor of the ASCO website, as well as Chair of ASCO’s Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog intended to help prostate cancer patients and their families.

Disclosures:

Articles by L. Michael Glodé, MD, FACP

The Case for Standard Imaging

L. Michael Glodé, MD, FACP, Professor Emeritus of Medical Oncology and the former Robert Rifkin Chair for Prostate Cancer Research at the University of Colorado Cancer Center in Aurora, Colorado, presents the case for standard imaging over second-generation technology in urologic oncology. One compelling reason to consider standard imaging like bone scans is the extensive data that have culminated in criteria on when to order routine scans such as these. Advanced imaging currently lacks both the wealth of data and scanning criteria, leading to questions about the frequency of false positives and false negatives and whether radiologist training is consistent. Dr. Glodé observes that we understand the limitations of conventional imaging, adding that there is insufficient data to make any such determination about the accuracy of second-generation scans. Since trials studying second-generation anti-androgens over the last few years have employed conventional imaging, Dr. Glodé suggests the more sensitive second-generation imaging could potentially deny patients with now-visible metastases access to some drugs based on eligibility criteria. The cost of newer imaging techniques is also prohibitive, especially if they do not replace current scans or change approaches to treatment. He concludes that the level 1 evidence on treatment of non-metastatic castration-resistant prostate cancer using conventional scans weighed against the cost of second-generation scans and the potential for inconsistent application of newer technology suggest that doctors should better utilize current standard imaging.

Read More

TMPRSS2, ACE 2, and the Potential Role of 5ARIs and GNRH Analogues in Inhibiting COVID-19 Infection

L. Michael Glodé, MD, FACP, Professor Emeritus at the University of Colorado Cancer Center and a medical oncologist at the Shaw Regional Cancer Center in Edwards, Colorado, discusses the mechanism of action of the TMPRSS2 and ACE2 pathways, and their relationship to the host-cell entry of COVID-19. He goes on to discuss a clinical trial using the serine protease inhibitor Camostat, noting how 5ARIs and GNRH analogues could act as a target for prevention and possible treatment of COVID-19. He also discusses the results of an Italian observational study which demonstrated how prostate cancer patients receiving ADT appear to be partially protected from COVID-19 infection.

Read More

Join the GRU Community

- Why Join? -